Celcuity 

Celcuity is proud to partner with Komen across several educational initiatives, including the Know More  Educational Series and the Metastatic Breast Cancer (MBC) Impact Series. Together, we believe that we can make a meaningful impact on patients’ lives.

About Celcuity: Pursuing a New Standard of Care in Breast Cancer

Celcuity is a commercial biotechnology company developing targeted therapies for multiple solid tumor cancers. Our mission is to extend the lives of cancer patients by developing first-in-class treatment options for cancers involving the PI3K/AKT/mTOR (PAM) pathway. PAM is one of the most important, and difficult to blockade, pathways that play a key role in driving cancer progression in various tumor types, including breast cancer.

More information about Celcuity can be found at www.celcuity.com.